1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Chemotherapy Induced Neutropenia - Pipeline Review, H1 2017

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2017

  • March 2017
  • -
  • Global Markets Direct
  • -
  • 107 pages

Summary

Table of Contents

Search Inside

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia – Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Neutropenia (Oncology) pipeline landscape.

Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. The predisposing factors include age, co-morbidities and time course of therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Neutropenia – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Neutropenia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 4, 5, 8, 1, 13, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Chemotherapy Induced Neutropenia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Neutropenia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Neutropenia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Neutropenia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Neutropenia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.